Noxxon Pharma
Noxxon Pharma AG is a Biopharma company pioneering the development of a new class of proprietary therapeutics called Spiegelmers, the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics:anti-CCL2/MCP-1 Spiegelmer® NOX-E36 for diabetic nephropathy / anti-CXCL12/SDF-1 Spiegelmer® NOX-A12 for oncology / anti-hepcidin Spiegelmer® NOX-H94 for anemia of chronic disease. The Spiegelmer platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation.
Sector
Biopharmaceuticals
Strategies
Status
Exit
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.